Please login to the form below
major depressive disorder
This page shows the latest major depressive disorder news and features for those working in and with pharma, biotech and healthcare.
Low-dose LSD looks safe for Alzheimer’s patients, but will it work?
Eleusis’ trial comes after the non-profit Usona Institute launched a phase 2 trial of psilocybin – found in ‘magic mushrooms’ – as a treatment for major depressive disorder.
Latest news
-
Sage slides off a MOUNTAIN as depression drug flunks trial
The company has just revealed that the pivotal phase 3 MOUNTAIN trial of its drug SAGE-217 – also known as zuranolone – missed its primary endpoint in major depressive disorder (MDD), wiping
-
Acadia’s drive to extend use of Nuplazid hits a wall
treatment for psychotic symptoms in other diseases, including schizophrenia, dementia and major depressive disorder.
-
Pear Therapeutics submits latest digital therapeutic, insomnia and depression treatment
SUD). It then followed this up with the approval in December 2018, of reSET-O, for the treatment of Opioid Use Disorder, which it co-markets with Novartis subsidiary Sandoz.. ... to develop a similar CBT-based app for the treatment of major depressive
-
Sage’s postpartum depression treatment Zulresso gains US approval
Brody says the ability to rapidly reduce symptoms in the disorder was an “exciting milestone in women’s mental health.”. ... Analysts forecast sales in excess of $1bn for the compound if it can gain approval in PPD and in the larger patient group
-
Depression drug failure adds to Allergan's woes
Axe hangs over remaining monotherapy and suicidality trials. Allergan’s novel treatment for major depressive disorder (MDD) rapastinel has failed in three pivotal phase 3 studies. ... The misfiring of rapastinel is a major blow for the company’s most
More from news
Approximately 7 fully matching, plus 56 partially matching documents found.
Latest Intelligence
-
Leo has its eyes on the prize
condition and the promise of major therapeutic breakthroughs. ... major depressive disorder and iron-deficiency anaemia.
-
Pharma deals continue to slide
74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset acquisition. CERC-501 phase II oral kappa opioid receptor antagonist for adjunctive treatment of major depressive disorder.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine
- Gut instincts lead Takeda to GI pipeline success
- How will the events and exhibitions industry change post-Coronavirus?
- Novavax reports promising phase 1 results for coronavirus vaccine
- Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops
- A new era for patient services?
- Live Webinar: Examining the Interface Between Healthcare & Society
- Novavax reports promising phase 1 results for coronavirus vaccine
- Merck enters agreement with Hanmi for investigational NASH drug
- AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
- Virtual Engagement At Porterhouse: Reflections on the past few months
- July 2020: diversity and inclusion in clinical trials round-up
PMHub
bmore group
OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- ...
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
